Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension

Massimo Volpe, Zhu Junren, Thomas Maxwell, Aldo Rodriguez, Raul Gamboa, Pablo Gomez-Fernandez, Ginés Ortega-Gonzalez, Norberta Matadamas, Freddy Rodriguez, Badal Dass, Chris Kyle, Laurent Clarysse, Alfonso Bryce, Ernesto Moreno-Heredia, Giuseppe Germano, Leen Gilles, Ronald D. Smith, John E. Sanderson

Research output: Contribution to journalArticle

Abstract

Background: Elevated systolic blood pressure is a more important risk factor for cardiovascular and renal disease than elevated diastolic blood pressure. Isolated systolic hypertension (ISH) is the predominant form of hypertension in the elderly. Effects of angiotensin II on the vascular wall and endothelium may contribute to development of ISH. Objective: The primary objective of this study was to compare the effects on trough sitting systolic blood pressure (SiSBP) of a regimen of losartan, a selective angiotensin II-receptor antagonist, and an amlodipine-based regimen in patients with ISH. Methods: This multicenter, prospective, randomized, double-blind, parallel-group study consisted of a 4-week placebo phase and an 18-week active-treatment phase. The losartan-based regimen consisted of losartan 50 mg, increased as needed to losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg at week 6 and to losartan 100 mg/HCTZ 25 mg at week 12 to achieve a target SiSBP

Original languageEnglish
Pages (from-to)1469-1489
Number of pages21
JournalClinical Therapeutics
Volume25
Issue number5
DOIs
Publication statusPublished - May 1 2003

Fingerprint

Amlodipine
Losartan
Blood Pressure
Hypertension
Hydrochlorothiazide
Angiotensin II Type 1 Receptor Blockers
Vascular Endothelium
Angiotensin II
Cardiovascular Diseases
Placebos
Kidney

Keywords

  • Angiotensin II-receptor antagonist
  • Isolated systolic hypertension
  • Losartan

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension. / Volpe, Massimo; Junren, Zhu; Maxwell, Thomas; Rodriguez, Aldo; Gamboa, Raul; Gomez-Fernandez, Pablo; Ortega-Gonzalez, Ginés; Matadamas, Norberta; Rodriguez, Freddy; Dass, Badal; Kyle, Chris; Clarysse, Laurent; Bryce, Alfonso; Moreno-Heredia, Ernesto; Germano, Giuseppe; Gilles, Leen; Smith, Ronald D.; Sanderson, John E.

In: Clinical Therapeutics, Vol. 25, No. 5, 01.05.2003, p. 1469-1489.

Research output: Contribution to journalArticle

Volpe, M, Junren, Z, Maxwell, T, Rodriguez, A, Gamboa, R, Gomez-Fernandez, P, Ortega-Gonzalez, G, Matadamas, N, Rodriguez, F, Dass, B, Kyle, C, Clarysse, L, Bryce, A, Moreno-Heredia, E, Germano, G, Gilles, L, Smith, RD & Sanderson, JE 2003, 'Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension', Clinical Therapeutics, vol. 25, no. 5, pp. 1469-1489. https://doi.org/10.1016/S0149-2918(03)80133-9
Volpe, Massimo ; Junren, Zhu ; Maxwell, Thomas ; Rodriguez, Aldo ; Gamboa, Raul ; Gomez-Fernandez, Pablo ; Ortega-Gonzalez, Ginés ; Matadamas, Norberta ; Rodriguez, Freddy ; Dass, Badal ; Kyle, Chris ; Clarysse, Laurent ; Bryce, Alfonso ; Moreno-Heredia, Ernesto ; Germano, Giuseppe ; Gilles, Leen ; Smith, Ronald D. ; Sanderson, John E. / Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension. In: Clinical Therapeutics. 2003 ; Vol. 25, No. 5. pp. 1469-1489.
@article{8362fbecaa464823ae8de21e807a7247,
title = "Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension",
abstract = "Background: Elevated systolic blood pressure is a more important risk factor for cardiovascular and renal disease than elevated diastolic blood pressure. Isolated systolic hypertension (ISH) is the predominant form of hypertension in the elderly. Effects of angiotensin II on the vascular wall and endothelium may contribute to development of ISH. Objective: The primary objective of this study was to compare the effects on trough sitting systolic blood pressure (SiSBP) of a regimen of losartan, a selective angiotensin II-receptor antagonist, and an amlodipine-based regimen in patients with ISH. Methods: This multicenter, prospective, randomized, double-blind, parallel-group study consisted of a 4-week placebo phase and an 18-week active-treatment phase. The losartan-based regimen consisted of losartan 50 mg, increased as needed to losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg at week 6 and to losartan 100 mg/HCTZ 25 mg at week 12 to achieve a target SiSBP",
keywords = "Angiotensin II-receptor antagonist, Isolated systolic hypertension, Losartan",
author = "Massimo Volpe and Zhu Junren and Thomas Maxwell and Aldo Rodriguez and Raul Gamboa and Pablo Gomez-Fernandez and Gin{\'e}s Ortega-Gonzalez and Norberta Matadamas and Freddy Rodriguez and Badal Dass and Chris Kyle and Laurent Clarysse and Alfonso Bryce and Ernesto Moreno-Heredia and Giuseppe Germano and Leen Gilles and Smith, {Ronald D.} and Sanderson, {John E.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S0149-2918(03)80133-9",
language = "English",
volume = "25",
pages = "1469--1489",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension

AU - Volpe, Massimo

AU - Junren, Zhu

AU - Maxwell, Thomas

AU - Rodriguez, Aldo

AU - Gamboa, Raul

AU - Gomez-Fernandez, Pablo

AU - Ortega-Gonzalez, Ginés

AU - Matadamas, Norberta

AU - Rodriguez, Freddy

AU - Dass, Badal

AU - Kyle, Chris

AU - Clarysse, Laurent

AU - Bryce, Alfonso

AU - Moreno-Heredia, Ernesto

AU - Germano, Giuseppe

AU - Gilles, Leen

AU - Smith, Ronald D.

AU - Sanderson, John E.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: Elevated systolic blood pressure is a more important risk factor for cardiovascular and renal disease than elevated diastolic blood pressure. Isolated systolic hypertension (ISH) is the predominant form of hypertension in the elderly. Effects of angiotensin II on the vascular wall and endothelium may contribute to development of ISH. Objective: The primary objective of this study was to compare the effects on trough sitting systolic blood pressure (SiSBP) of a regimen of losartan, a selective angiotensin II-receptor antagonist, and an amlodipine-based regimen in patients with ISH. Methods: This multicenter, prospective, randomized, double-blind, parallel-group study consisted of a 4-week placebo phase and an 18-week active-treatment phase. The losartan-based regimen consisted of losartan 50 mg, increased as needed to losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg at week 6 and to losartan 100 mg/HCTZ 25 mg at week 12 to achieve a target SiSBP

AB - Background: Elevated systolic blood pressure is a more important risk factor for cardiovascular and renal disease than elevated diastolic blood pressure. Isolated systolic hypertension (ISH) is the predominant form of hypertension in the elderly. Effects of angiotensin II on the vascular wall and endothelium may contribute to development of ISH. Objective: The primary objective of this study was to compare the effects on trough sitting systolic blood pressure (SiSBP) of a regimen of losartan, a selective angiotensin II-receptor antagonist, and an amlodipine-based regimen in patients with ISH. Methods: This multicenter, prospective, randomized, double-blind, parallel-group study consisted of a 4-week placebo phase and an 18-week active-treatment phase. The losartan-based regimen consisted of losartan 50 mg, increased as needed to losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg at week 6 and to losartan 100 mg/HCTZ 25 mg at week 12 to achieve a target SiSBP

KW - Angiotensin II-receptor antagonist

KW - Isolated systolic hypertension

KW - Losartan

UR - http://www.scopus.com/inward/record.url?scp=0037945481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037945481&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(03)80133-9

DO - 10.1016/S0149-2918(03)80133-9

M3 - Article

C2 - 12867222

AN - SCOPUS:0037945481

VL - 25

SP - 1469

EP - 1489

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 5

ER -